0001209191-22-007915.txt : 20220208 0001209191-22-007915.hdr.sgml : 20220208 20220208210945 ACCESSION NUMBER: 0001209191-22-007915 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220204 FILED AS OF DATE: 20220208 DATE AS OF CHANGE: 20220208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doyle Ramona CENTRAL INDEX KEY: 0001856069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 22603562 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-04 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856069 Doyle Ramona C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 Chief Medical Officer Class A Common Stock 2022-02-04 4 A 0 38499 0.00 A 95834 D Class A Common Stock 2022-02-04 4 A 0 2392 0.00 A 98226 D Class A Common Stock 2022-02-04 4 F 0 981 11.40 D 97245 D Stock Option (Right to Buy) 11.40 2022-02-04 4 A 0 76998 0.00 A 2032-02-04 Class A Common Stock 76998 76998 D Stock Option (Right to Buy) 11.40 2022-02-04 4 A 0 4784 0.00 A 2022-02-04 2032-02-04 Class A Common Stock 4784 4784 D Stock Option (Right to Buy) 2.48 2030-12-30 Class A Common Stock 694053 694053 D This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter. This RSU vested immediately upon the grant date. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. /s/ Nathan Hatfield, attorney-in-fact 2022-02-08